HUENENBERG, Switzerland Alcon has completed its purchase of LenSx Lasers, and the transaction has cleared Federal Trade Commission review, according to a company official.
“We are really excited about this acquisition. It is a terrific marriage between a world-class technology and a terrific technological achievement from the LenSx team and a commercial structure at Alcon that can help our customers take advantage of this technology globally,” Stuart Raetzman, vice president of global marketing and U.S. area president for Alcon, said in an interview with .
The LenSx femtosecond laser has been approved by the U.S. Food and Drug Administration for anterior capsulotomy and lens fragmentation during cataract surgery, as well as full- and partial-thickness corneal incision for keratoplasty, according to Mr. Raetzman.
Alcon paid LenSx shareholders a base purchase price of $361.5 million with maximum contingent payments of $382.5 million based on future revenue milestones, according to company reports.
“We’ll keep the LenSx brand and LenSx will become the name of the product line, and the facility in Aliso Viejo will be their R&D center of excellence,” Mr. Raetzman said. “This is a marriage of a great technology that was developed by a really bright group of scientists and business leaders and a commercial organization like Alcon that can help doctors gain access to it quickly.”
Similar Posts:
- NovaBay, Alcon terminate collaboration agreement
- Combined Express Scripts/Medco May Face Off Against UnitedHealth Unit
- Smooth Those Facial Lines With A Cyber Pen
- Superbug antibiotics: Research and pipeline
- A.M. Vitals: Dannon to Pay $21 Million to Settle Probiotics Complaints
